These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24090103)

  • 21. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
    Roecker AJ; Coleman PJ
    Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
    Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
    J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward the Mysteries of Sleep.
    Yanagisawa M
    Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer's plaque pathology.
    Dhanjal JK; Goyal S; Sharma S; Hamid R; Grover A
    Biochem Biophys Res Commun; 2014 Jan; 443(3):1054-9. PubMed ID: 24365147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus.
    Beig MI; Horiuchi J; Dampney RA; Carrive P
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1059-67. PubMed ID: 26174505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
    Yamamoto N; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
    Bioorg Med Chem; 2019 Apr; 27(8):1747-1758. PubMed ID: 30871861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the orexin (hypocretin) system in contextual fear conditioning in rats.
    Wang H; Li S; Kirouac GJ
    Behav Brain Res; 2017 Jan; 316():47-53. PubMed ID: 27575948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioactive compounds from Ocimum tenuiflorum and Poria cocos: A novel natural Compound for insomnia treatment based on A computational approach.
    Ranteh O; Tedasen A; Rahman MA; Ibrahim MA; Sama-Ae I
    Comput Biol Med; 2024 Jun; 175():108491. PubMed ID: 38657467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
    Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
    Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
    Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
    Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
    Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of New Orexin 2 Receptor Modulators Using
    Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A.
    Messal N; Fernandez N; Dayot S; Gratio V; Nicole P; Prochasson C; Chantret I; LeGuilloux G; Jarry A; Couvelard A; Tréton X; Voisin T; Ogier-Denis E; Couvineau A
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3618-3628. PubMed ID: 30251681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.
    Karhu L; Turku A; Xhaard H
    BMC Struct Biol; 2015 May; 15():9. PubMed ID: 25957175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
    Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.
    Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M
    J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
    Coleman PJ; Cox CD; Roecker AJ
    Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
    Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.